PIH1 EMERGENCY CONTRACEPTION FOR UNINTENDED PREGNANCY: ROLE OF ULIPRISTAL, A NOVEL PROGESTERONE RECEPTOR MODULATOR  by Aggarwal, A
A374 13th Euro Abstracts
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
PGI29
PPI GENERAL PRACTITIONERS’ PRESCRIBING IN THE TREATMENT OF 
ACID-RELATED DISORDERS: THE IMPACT OF GENERIC PPI LAUNCH 
INTO THE PHARMACEUTICAL MARKET IN ITALY
Cammarota S1, Sarnelli G2, Citarella A1, Menditto E1, Riegler S1, Bruzzese D2, Cuomo R2
1CIRFF, Federico II University, Naples, Italy; 2Federico II University Hospital School of 
Medicine, Naples, Italy
OBJECTIVES: To investigate the phenomenon of PPI switching in the acid related 
disorders treatment in an Italian primary care setting during 2005–2008 (before and 
after PPIs’ patents expired) and to estimate the costs of health care resources consump-
tion associated with this phenomenon. METHODS: Retrospective cohort study was 
performed analyzing data from 127 GPs of Naples in the south of Italy. PPI users for 
ARD treatment within each study year were selected from source population. Switch-
ers were deﬁ ned patients changing from one PPI to another within each study year. 
Multivariate logistic regressions were used to assess the potential predictors of PPI 
switching and to investigate the factors inﬂ uencing the direction of the switch. Cost 
was expressed as Euro 2008 per PPI user. RESULTS: The phenomenon of PPI switch-
ing rose from 13.0% in 2005 to 16.7% in 2008 with a peak of 18.8% in 2006. 
Calendar years, long-term treatments and GERD diagnosis were positive predictors 
of PPI switching. All years analyzed (versus 2005) were associated with switching to 
lansoprazole while the 2008 year was strongly associated with switching to omepra-
zole and pantoprazole. Very long-term treatment (>11 pack/years) group accounted 
for 66.3% of the total primary care cost. Switchers increased primary care costs by 
c61.1 compared with no switchers, reaching an incremental cost of c133.1 per user-
year in the case with more than 1 switch. CONCLUSIONS: In Italy the launch of 
generic PPIs in the national market generates the increasing amount of chronic treat-
ments and therapeutic substitution that will probably have had a negative impact on 
the total savings on PPIs, achievable by the introduction of generic products. Policy 
rules favouring generic PPIs prescribing can often inﬂ uence physicians’ decision to 
select the appropriate treatment for each patient.
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ASSESSMENT OF FEASIBILITY OF THE METHODOLOGICAL APPROACH 
DESCRIBED IN THE MODEL FOR THE REGULATION OF 
REIMBURSEMENT PRICES IN GERMANY
Aidelsburger P1, Benkert D1, Neumann A2, Niebuhr D3, Wasem J2
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OBJECTIVES: The generic drug market within the statutory health insurance (SHI) 
in Germany is affected by price regulations like ﬁ xed amounts or rebats. Legal amend-
ments led to an increasing importance of price discounts with uncertain impact on 
pharmaceutical supply of the patients. To assure a justiﬁ able price for the pharma-
ceutical companies and high quality a model has been developed by the Federal 
Association of Medicines Manufacturers e. V. (BAH) for the regulation of reimburse-
ment prices, e.g. cost-beneﬁ t based price corridors. Aim of the study is to test the 
described methods for feasibility. METHODS: The prior published methods for the 
development of reimbursement price corridors are applied and tested for feasibility by 
use of the indication Gastroesophageal Reﬂ ux Disease (GERD). The methods intend 
the derivation of one or more corridors following a deﬁ ned decision algorithm based 
on primary and secondary beneﬁ t criteria. Therefore a systematic assessment of ben-
eﬁ ts of proton pump inhibitors (PPIs), H2-Blockers and sucralfat is the foundation of 
further decisions concerning the number of corridors to consider. Several methodical 
approaches for the deﬁ nition of height of each corridor are tested. RESULTS: PPIs 
are more effective than H2-Blocker or sucralfat concerning primary beneﬁ t endpoints. 
The assessment is based on secondary literature for ﬁ nancial and time reasons that 
will be relevant when implementing the model in real decision problems, too. Based 
on the results of the beneﬁ t assessment two corridors were implemented into the 
model. The height of each corridor can be derivated by use of angles as well as by 
other mathematical parameters like mean, quartiles etc. Both approaches show speciﬁ c 
limitations. CONCLUSIONS: The feasibility of the reported concept can be shown. 
Several limitations, e.g. assessment of beneﬁ ts based on secondary literature should 
be considered. Use of angles or mathematical parameter should be discussed with 
decision makers before implementation.
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EVALUATING THE POST OPERATIVE PRESCRIBING PRACTICES FOR 
APPENDICITIS IN PUBLIC HEALTH FACILITIES IN PAKISTAN
Malik M, Hussain A, Abassi N, Khan J
Hamdard University, Islamabad, Punjab, Pakistan
OBJECTIVES: To investigate the pattern of prescribing practices for postoperative 
appendicitis in public health facilities. METHODS: The study population consisted 
of the largest public hospital Federal Government Services Hospital (Polyclinic) from 
Punjab, Pakistan; Islamabad. a sample of 100 prescriptions of post operative appen-
dicitis was collected from the public hospital. RESULTS: A total of 13.3% prescrip-
tions out of 100 contain 2 drugs, 40% contains 3 drugs, 40 % contains 4 drugs & 
6.7% contains 5 dugs. Only 6.7% prescriptions contain drugs prescribed by generic 
while 93.3% prescriptions were not prescribed by generic name. a total of 3.3% 
prescriptions contain no antibiotics, 76.6% prescriptions contain 1 antibiotic, while 
20% prescriptions contain 2 antibiotics. On the other hand 23.3% prescription does 
not contain any injection, 10% prescriptions contain 2 injections, 23.3% prescriptions 
contain 3 injections, while 43.3% prescriptions contain 4 injections. One hundred 
percent of prescribers suggested that standard treatment guidelines and essential drug 
list should be available and updated regularly in hospital and must be strictly followed. 
a total of 33.3% of prescribers think the essential drug list should be properly regu-
lated and updated should by the hospital management, 33.3% prescribers think by 
Ministry of Health while 33.3% prescribers thinks it is the duty of Hospital pharma-
cist. This difference was noted with respect to age of the prescriber (p = 0.020) in the 
prescribing practice of physicians in the public health facility. CONCLUSIONS: The 
major reasons for irrational drug use in case of post operative appendicitis were due 
to polypharmacy, overuse of antibiotics and injection and lack of standard treatment 
guidelines in the hospital. Thus the extent of irrational drug use in the public sector 
calls for in-depth investigation of the system factors and motivations that underlying 
these problems in the practice and the development of interventions that target the 
causative factors of inappropriate prescribing practice in Pakistan. 
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USING DATA ENVELOPMENT ANALYSIS TO ESTABLISH THE 
EFFECTIVENESS EVALUATION OF DRUGS
Wu ML
Taichung Veterans General Hospital, Taichung City, Taiwan
OBJECTIVES: The development and research in pharmaceutical industry has con-
stantly created new listing drugs which provide more therapeutic effect and lower 
side-effects than former drugs, but the price become more expensive relatively. In order 
to balance the trade-off between medical quality and cost reduction, hospitals have 
to make the decision-making between the former drugs and the new listing drugs, 
which have similar therapeutic effectiveness. In this regard, the most primary issue in 
this research to solve is to establish a more objective and efﬁ cient decision-making 
analysis that consider both effectiveness and cost for the drugs which have the similar 
therapeutic effect. METHODS: We use data envelopment analysis (DEA) to solve this 
problem, We screen six critical factors, daily drug expenses, drug proﬁ ts, side-effect, 
consumption, patent duration and lead time. Evaluation of relative efﬁ ciency of the 
option with DEA method must be built on the relative performance data of every 
input or output attributes of each decision-making unit. RESULTS: This study uses 
four kinds of proton pump inhibitors (PPI) for effectiveness evaluation (the code A, 
B, C, D drugs to replace its original name), ﬁ rst according to deﬁ nition of the factors 
to collect relevant data. We use the DEA method to treat these data, Drug a in the 
DEA method analysis results is the most effective (6.6542E-06), Drug D is the second 
(4.2381E-06), Drug B is the third (2.1165E-06) and Drug C is the worst (1.2786E-06). 
CONCLUSIONS: Through this research model, we transfer complex decision-making 
goals into various measurable or comparable factors that can compare the relative 
importance. The evaluation result may not let all decision-makers and users to adopt 
at all. But it is more comprehensive and objective to evaluate the effectiveness of 
decision-making models than that in the past. 
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EMERGENCY CONTRACEPTION FOR UNINTENDED PREGNANCY: ROLE 
OF ULIPRISTAL, A NOVEL PROGESTERONE RECEPTOR MODULATOR
Aggarwal A
Heron Health Private Ltd, Chandigarh, India
OBJECTIVES: Unintended pregnancies represent a global health problem with over 
80 million annual pregnancies. These are associated with an increased risk of morbid-
ity and a considerable impact on women’s quality-of-life. Globally, 38% of all preg-
nancies are unintended resulting in 42 million induced abortions and 34 million 
unintended births. This corresponds to 43% of all child-births worldwide. a novel 
drug “Ulipristal” was introduced in Europe in May 2009 with efﬁ cacy beyond 72 
hours after unprotected coitus. The objective of this review was to determine the safety 
and efﬁ cacy proﬁ le of ulipristal compared to levonorgestrel. METHODS: A number 
of databases (PUBMED, EMBASE, POPLINE, CENTRAL and clinicaltrials.gov) were 
searched and the citations screened to identify randomised controlled trials (RCTs) 
reporting efﬁ cacy and safety outcomes of ulipristal. Grey literature was searched to 
identify the cost associated with unintended pregnancies. Summary-statistics (Ran-
dom-Effects: DerSimonian-Laird) were used to assess pregnancy and adverse-events 
outcomes. RESULTS: Seven RCTs were identiﬁ ed and only two reported pregnancy 
outcomes. In a pooled analyses when compared to levonorgestrel, ulipristal showed 
better efﬁ cacy results in preventing pregnancy following unprotected coitus on day 1 
and day 3 (Day 1, RR = 0.435, [95%CI:0.148, 1.279] and Day 3, RR = 0.376, 
[95%CI:0.110, 1.283]). However, these results were non-signiﬁ cant. Conversely, sub-
group analysis showed that if administered on day 2, this trend was reversed with 
administration of levonorgestrel being associated with fewer pregnancies (RR = 1.309, 
[95%CI: 0.572, 2.996]). The frequency of adverse events like nausea, headache, 
fatigue and dizziness was similar with both the drugs. Unintended pregnancies were 
found to be associated with huge costs that amounted up to US$ 5 billion in US during 
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2002 and £335 million in UK during 2001. CONCLUSIONS: Ulipristal appears as 
effective as levonorgestrel in preventing unintended pregnancies with similar safety 
proﬁ le. Substantial cost-savings can be expected with appropriate awareness programs 
about emergency contraceptives among women.
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PEDIATRIC INTENSIVE CARE UNIT (PICU) ADMISSIONS FOR 
RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE ERA OF 
PALIVIZUMAB PROPHYLAXIS
Paes BA1, Butt M1, Janes M2, Symington A2, Elliott L2, Steele S1
1McMaster University, Hamilton, ON, Canada; 2McMaster Children’s Hospital, Hamilton, ON, 
Canada
OBJECTIVES: To examine the characteristics of patients admitted to PICU with RSV 
infection following provincial approval of RSV prophylaxis in June 2002. Secondly, to 
determine if patients had received palivizumab and document incurred morbidities. 
METHODS: A retrospective, hospital medical records review of all PICU admissions 
for RSV infection from January 1, 2003 to December 31, 2009. RSV infection was 
identiﬁ ed by ICD codes and cases were conﬁ rmed by RSV IFA test, culture, or PCR. 
Data was collected on baseline demographics, underlying disease, criteria for hospi-
talization, type of respiratory illness and management, complications and palivizumab 
prophylaxis. Group 1 patients (≤2 years) were compared to Group 2 (>2–18 years). 
RESULTS: A total of 181 patients were admitted with RSV infection over 7 years. 
Group 1 (n = 152); Group 2 (n = 29) had a mean admission age in months (SD); 3.7 
(5.7) versus 59.9 (37.7). Majority (79.6%) Group 1 versus only 20.7% Group 2 (P 
< 0.001) had no underlying disease. 97.4% versus 93.1% were admitted with respira-
tory distress and most had bronchiolitis; 88.8% versus 55.2 % (P < 0.001), decreased 
oxygen saturation; 77% versus 75.9% and inability to maintain intake; 75.7% versus 
44.8% (P < 0.01). Fifty percent versus 41.3% required mechanical ventilation and 
81.6% versus 69.0% received antibiotics. Median days (range) in PICU was 5 (1–73) 
versus 2 (1–36). Median length of hospital stay days (range) was 9 (1–113) versus 7 
(1–64) (P < 0.05). The overall RSV positive, PICU hospitalization rate was 5.7%. 
There were few complications: respiratory (2.8%); concurrent bacterial sepsis (5.5%). 
Only 3.3% children had received prophylaxis. 1 death was attributed to RSV infec-
tion. CONCLUSIONS: Majority of admissions comprised infants ≤2 years of age. 
63.3% were ≥36 weeks gestation without underlying disease and in total 88.4% would 
not qualify for prophylaxis. Current Canadian RSV prophylaxis guidelines have sig-
niﬁ cantly impacted PICU admission rates in high-risk infants.
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PARENTERAL ALANYL-GLUTAMMINE IN CRITICALLY ILL PATIENTS: A 
BAYESIAN META-ANALYSIS OF PUBLISHED TRIALS
Pradelli L1, Zaniolo O1, Iannazzo S1, Eandi M2
1Adres srl, Torino, Italy; 2University of Torino, Torino, Italy
OBJECTIVES: Glutamine, although abundant in human tissue, can become condition-
ally essential in clinical conditions with hyper-catabolism and glutathione depletion 
(burns, pancreatic necrosis, surgical complications), but has not been added to paren-
teral nutrition solutions for a long time, for its alleged non-essentiality and the low 
solubility and stability in aqueous solutions, which have been solved by conjugation 
with alanine. In 2002 a meta-analysis of available trials conducted with alanylgluta-
mine dipeptide revealed signiﬁ cant reductions of mortality, infections and ICU length 
of stay. Since then, data from other trials have become available. Aim of the present 
study is to update the treatment effect estimates by means of a series of Bayesian 
random effects models. METHODS: We searched EMBASE and Medline for clinical 
trials of standard total parenteral nutrition (TPN) vs. TPN + parenteral alanylgluta-
mine in critically ill patients reporting hospital mortality, relative ICU-incident infec-
tion rate, and relative hospital length of stay. For each outcome, a series of Bayesian 
random effects models was speciﬁ ed, in which the treatment effect observed in the 
individual trials is assumed to be drawn from a common distribution and expressed 
as a relative risk or duration. RESULTS: Outcomes from 15 trials and 781 patients 
were retrieved. The main models, i.e. simple hierarchy random effects models with 
neutral priors, estimate a relative mortality of 0.70 (95% CrI: 0.46–0.97), a relative 
infection rate of 0.71 (95% CrI: 0.49–0.97), and a relative length of stay of 0.91 (95% 
CrI: 0.76–1.00). Secondary analyses indicated some heterogeneity in the magnitude 
and reliability of the beneﬁ ts in sub-groups of the wider critically ill patient population. 
The incorporation of prior knowledge leads to signiﬁ cantly more precise estimates and 
permits to obtain comfortable reliability even on subgroup-speciﬁ c treatment effects 
estimates. CONCLUSIONS: In conclusion, the available evidence supports a highly 
credible beneﬁ cial effect of alanylglutamine on mortality, infections and hospital 
length of stay in ICU-admitted critically ill patients.
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COMPARING THE MODEL PREDICTED VACCINE IMPACT AGAINST 
ROTAVIRUS HOSPITALIZATION WITH OBSERVED DATA IN BELGIUM
Standaert B1, Strens D2, Van Bellinghen LA3, Van Vlaenderen I2
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OBJECTIVES: In reimbursement ﬁ les models estimate the events avoided over time 
with new interventions. Simulations are performed in the absence of long-term obser-
vational data. In this study observed hospitalization data prior- and post-rotavirus 
vaccination in Belgium were compared to predicted (i.e. modeled) results after 1,2 and 
3 years. METHODS: A Markov cohort model estimated over time the number of 
hospitalizations potentially avoided with rotavirus vaccination in Belgium. We 
adjusted the model to the observed vaccine coverage and to RotarixTM vaccine efﬁ cacy 
from clinical trials. The obtained modeling results were compared with observed data 
collected from 9 Belgian hospitals (2 years pre- and 3 consecutive years post-vaccina-
tion). The outcomes of both studies are expressed as a percentual decrease in hospi-
talizations for 2 age-groups (<2 and <5 years old), after each year post-vaccination. 
The differences are presented in absolute and relative (%) differences for each subse-
quent year post-vaccine launch. RESULTS: The observed data provided slightly better 
outcomes than the modeled results. After 1 year the absolute difference in decrease of 
hospitalizations between observed and modeled data was 3% (11%) for both age-
groups. After 2 years the absolute differences were 3.5% (6%) and 6% (12%) for the 
2 y and 5 y age-group respectively. In the last observation year the absolute differences 
were respectively 2.8% (4%) and 9.3% (13%). CONCLUSIONS: Compared with the 
observed data the model estimates are conservative. The more favorable observational 
results are explained by the indirect vaccine effect on non-vaccinated age-groups which 
is not captured by the static model. The relatively better model ﬁ t in the <2 y old with 
increasing time is explained by the accumulated vaccine impact over time: from 26% 
(1st year) to 68% (3rd year). Rotarix is a trademark of the GlaxoSmithKline group of 
companies.
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PHARMACOEPIDEMIOLOGICAL BURDEN OF PREGNANCY IN BELARUS
Gavrilenko L, Romanova I, Kozhanova I
Belarusian State Medical University (BSMU), Minsk, Belarus
OBJECTIVES: Application of medicines during pregnancy is a challenge of clinical 
pharmacology. We have analyzed priorities of physicians while choosing medications 
in the course of various diseases during pregnancy and adherence of pregnant women 
to the appointed treatment in Belarus. METHODS: It was prospective multi-center 
cross-sectional epidemiological research. We interviewed 1334 pregnant women and 
619 physicians with diverse specialties in 6 regions of the country using a structured 
questionnaire from January to December 2009. All questionnaires have undergone 
statistical analysis. RESULTS: We found that 34.5% of the pregnant women who 
took part in questioning have had chronic diseases. Medical products were prescribed 
for 91.7% (1223) women. a total of 23.8% of them have received more than 5 medical 
products. Vitamins and drugs with microcells (magnesium, iodine, iron and calcium), 
herbal drugs (valerian, leonurus and eleutherococcus) were in the lead in structure of 
prescription. 91,8% of the pregnant women took all prescribed medicines. 7.7% (103) 
women took antibacterial medicines following recommendations of the doctor. a total 
fo 365 women (27.3%) took medicines without prescription (625 cases). Non-pre-
scribed drugs during pregnancy had mostly been recommended by family or friends 
(24.1% of women) and pharmacists in drugstores (24.1%). CONCLUSIONS: Preg-
nant women in Belarus are active consumers of medicines (vitamins, microcells, herbal 
drugs, bioadditives) themselves and with doctors’ prescription. The widespread use of 
medicines indicates an increased need for documentation and education about the 
safety of medicines in the course of pregnancy. Application of these medications 
creates additional ﬁ nancial burden (in addition to necessary medicines and products), 
and it does not necessarily positively inﬂ uence health. Educational programs for 
pharmacists, doctors and pregnant women are necessary for improvement of drug 
administration.
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IMPACT OF ROTAVIRUS VACCINATION ON ACUTE GASTROENTERITIS 
RELATED EMERGENCY ROOM VISITS IN CHILDREN ≤FIVE YEARS OLD 
IN BELGIUM
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OBJECTIVES: Belgium is one of the few countries to implement rotavirus vaccination 
within its universal paediatric immunization programme. This study was designed to 
measure the impact of rotavirus vaccination on acute gastroenteritis (AGE) related 
emergency room (ER) visits in children aged ≤5 years in Belgium. METHODS: A 
retrospective observational study was performed across 11 Belgian participating 
centres. Each centre provided an anonymised list of all ER visits of children aged ≤5 
years during the periods June 2004–May 2006 (pre-vaccine period) and June 2007–
May 2009 (post-vaccine). a sample of 7620 ER visits (3699 pre-vaccine; 3921 post-
vaccine) was randomly selected from the 180,253 ER visits reported. Patient 
demographics and information on the reason for ER visit were collected from all 
randomly selected visits. If the visit was AGE-driven, additional data were collected 
on vaccination status, symptoms, tests performed, treatment, and visit outcome. 
RESULTS: The proportion of AGE-driven ER visits was 11% in the 2-year pre-vaccine 
period (N AGE-driven visits/Total N ER visits = 412/3,699). After insigniﬁ cant change 
to 10.5% during the 1st year after vaccine introduction (N = 208/1,977), this propor-
tion signiﬁ cantly declined to 8.2% (26.6% reduction; p-value < 0.001) in the 2nd year 
(N = 159/1,944). a strong seasonal effect exists in the proportion of AGE-driven ER 
visits on the total number of ER visits, peaking in February and March. The number 
of patients who needed to be hospitalised because of AGE declined over time (from 
a yearly average of 94 pre-vaccine to 62 and then 44 in the 2 consecutive years post 
vaccine introduction). Oral and IV rehydration are the most commonly used treat-
ments. Their use also declined after vaccine introduction. CONCLUSIONS: A signiﬁ -
cant decline in AGE-driven ER visits and subsequent hospitalizations was observed in 
Belgium after introduction of a universal mass vaccination program against rotavirus. 
AGE cases appeared less severe.
